First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (SYNFRIZZ)
まず男研究では生体内分布、安全性、最適の推奨用量焦がしたホモログ 10 (SYNFRIZZ) をターゲット新しい放射性標識モノクローナル抗体の調査
Estimated Enrollment:18
Study Start Date:December 2011
Estimated Study Completion Date:December 2013
Estimated Primary Completion Date:December 2013 (Final data collection date for primary outcome measure)
Sponsors and Collaborators
Centre Leon Berard
OncoTherapy Science, Inc.
Investigators
Principal Investigator:
Jean-Yves BLAY, MD, PhD
Centre Léon Bérard
>>143547
参考に投稿します。
風邪を引いたみたいで、久しぶりに有給で休んでいたら
ClinicalTrials.gov で見ました。
First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (SYNFRIZZ)
まず男研究では生体内分布、安全性、最適の推奨用量焦がしたホモログ 10 (SYNFRIZZ) をターゲット新しい放射性標識モノクローナル抗体の調査
Sarcoma, Synovial滑膜肉腫
Drug: OTSA101-DTPA-90Y level 1 薬物： OTSA101 DTPA 90Y レベル 1 Drug: OTSA101-DTPA-90Y level 2 薬物： OTSA101 DTPA 90Y レベル 2
Drug: OTSA101-DTPA-90Y level 3薬物： OTSA101 DTPA 90Y レベル 3
Phase 1
Estimated Enrollment:18
Study Start Date:December 2011
Estimated Study Completion Date:December 2013
Estimated Primary Completion Date:December 2013 (Final data collection date for primary outcome measure)
Sponsors and Collaborators
Centre Leon Berard
OncoTherapy Science, Inc.
Investigators
Principal Investigator:
Jean-Yves BLAY, MD, PhD
Centre Léon Bérard
ClinicalTrials.gov processed this record on December 06, 2012
ClinicalTrials.gov は、2012 年 12 月 6 日にこのレコードを処理
http://clinicaltrials.gov/ct2/show/NCT01469975?term=OncoTherapy+Science%2C+Inc.%EF%BC%88&rank=1